Pharmacokinetics of MDMA

作者: Enno Freye

DOI: 10.1007/978-90-481-2448-0_25

关键词:

摘要: Effects of MDMA usually begin 30–45 min after oral administration a 75–150 mg dose with peak effects occurring 60–90 ingestion, which start to diminish 2 h, however lasting up 8 h (Table 3). The time maximum concentration (Tmax) is ingestion 50, 75, or 125 mg. half-life shows little variation wide range doses. After 50-, 75-, 125-mg dose, the [49]. Other studies found be 9.53 75-mg and 9.12 [50]. (Cmax) appears dependent. A Cmax 105.6 ng/ml was reported in single subject who took 50-mg [51], whereas 330 another 135 [52]. In group eight subjects, values 75 were 126.5 226.3 ng/ml, respectively [50], 130.9 236.4 obtained mg, These indicate, that exhibits slightly greater-than-expected increase compared dose. According these observations, following usual recreational 100–150 should 200–300 ng/ml. area under concentration-time curve (AUC) data from also suggests nonlinearity. AUC measured over 24 (2,235.9 µg/l/h) more than twice (995.4 µg/l/h Nonlinearity further supported by other evidence, ratio 1:3 (50 150 mg), greater 1:10. authors suggested non-renal clearance

参考文章(67)
Michael J A Parr, Heather M Low, Pauli Botterill, Hyponatraemia and death after "ecstasy" ingestion. The Medical Journal of Australia. ,vol. 166, pp. 136- 137 ,(1997) , 10.5694/J.1326-5377.1997.TB140044.X
C. SINGARAJAH, N. G. LAVIES, An overdose of ecstasy. A role for dantrolene. Anaesthesia. ,vol. 47, pp. 686- 687 ,(1992) , 10.1111/J.1365-2044.1992.TB02391.X
M Hiramatsu, A K Cho, Y Kumagai, S E Unger, Metabolism of methylenedioxymethamphetamine: formation of dihydroxymethamphetamine and a quinone identified as its glutathione adduct. Journal of Pharmacology and Experimental Therapeutics. ,vol. 254, pp. 521- 527 ,(1990)
M. Farre, M. Mas, J. Ortuno, J. Cami, P. N. Roset, J. Segura, R. De La Torre, Cardiovascular and Neuroendocrine Effects and Pharmacokinetics of 3,4-Methylenedioxymethamphetamine in Humans Journal of Pharmacology and Experimental Therapeutics. ,vol. 290, pp. 136- 145 ,(1999)
N.T.A. Campkin, U.M. Davies, Treatment of ‘ecstasy’ overdose with dantrolene Anaesthesia. ,vol. 48, pp. 82- 83 ,(2007) , 10.1111/J.1365-2044.1993.TB06811.X
B Tehan, Ecstasy and dantrolene. BMJ. ,vol. 306, pp. 146- 146 ,(1993) , 10.1136/BMJ.306.6870.146
Jamyl Alrazi, The Complications of 'Ecstasy' (MDMA) JAMA: The Journal of the American Medical Association. ,vol. 259, pp. 1649- 1650 ,(1988) , 10.1001/JAMA.1988.03720110019021
John A Henry, John K Fallon, Andrew T Kicman, Andrew J Hutt, David A Cowan, Mary Forsling, Low-dose MDMA (“ecstasy”) induces vasopressin secretion The Lancet. ,vol. 351, pp. 1784- 1784 ,(1998) , 10.1016/S0140-6736(05)78744-4
Donna Ames, Ecstasy, the Serotonin Syndrome, and Neuroleptic Malignant Syndrome—A Possible Link? JAMA: The Journal of the American Medical Association. ,vol. 269, pp. 869- 870 ,(1993) , 10.1001/JAMA.1993.03500070049022
T. Randall, Ecstasy-fueled 'rave' parties become dances of death for English youths JAMA: The Journal of the American Medical Association. ,vol. 268, pp. 1505- 1506 ,(1992) , 10.1001/JAMA.268.12.1505